Faced with a CRO delivering slow recruitment, disengaged sites, and delayed data management in its Phase 2 oncology study, this biotech decided to pivot and bring in a new CRO. They came to Worldwide requesting the hands-on, proactive support they’d heard Worldwide could deliver. Check out this case study to see how the transition went and what the outcomes were for this study.
See how Worldwide addressed the following challenges caused by the outgoing CRO in this Phase 2 oncology transition trial:
- Slow patient recruitment
- Disengaged sites
- Delays in data management
